Time | Abstract # | Topic | Speaker |
---|---|---|---|
6:00 – 7:00 AM | Poster Set Up | N/A | |
7:00 – 8:00 AM | Breakfast, Networking, and Poster Viewing | N/A | |
8:00 AM – 8:20 AM | Welcome address from the symposia chairs | Davinder Parsad, MD, and Samia Esmat, MD |
Basic Science – Moderator: Thierry Passeron, MD, PhD
Chairperson: Dr. Yogesh Marfatia, and Dr. Emy Thomas
Time | Abstract # | Topic | Presenter |
---|---|---|---|
8:20 AM – 8:50 AM | Invited Speaker: Possible Source of the Intracellular Oxidative Stress in Vitiligo | Mauro Picardo, MD
Click the presenter’s name for additional information. | |
8:50 AM – 9:00 AM | 165 | Elevated IFN-γ in Vitiligo Patient Skin Blisters: Potential Utility of Targeting IFN-γ for Therapy | Chau Yee Ng, MD, PhD |
9:00 AM – 9:10 AM | 184 | Compromised Melanocyte Survival Due to Decreased Suppression of CD4+ & CD8+ Resident Memory T Cells by Impaired TRM-Regulatory T Cells in Generalized Vitiligo | Firdosh Shah, MSc |
9:10 AM – 9:20 AM | 169 | Differential Expression of Serum CXCL9 and CXCL10 in Vitiligo Patients and Their Correlation With Disease Severity and Stability | Shayna Aulakh, MBBS, MD |
9:20 AM – 9:30 AM | 174 | Early Localized Vitiligo is not “EARLY”: A Tissue Resident Memory T Cell Study | Hisham Hamdy, MBBS, MSc |
9:30 AM – 9:40 AM | 216 | Assessing Expression of Immune Checkpoints Including Membrane-Bound and Soluble Programmed Death-1 Receptor and Ligands in Vitiligo and Correlating These With Serum Levels of Interleukin 2, 7, 15 and Vitiligo Disease Severity | Anuradha Bishnoi, MD |
9:40 AM – 9:50 AM | 182 | Oxidative Stress in Segmental Versus Non-Segmental Vitiligo | Nader Ragab, MD |
9:50 AM – 10:05 AM | Panel Q&A | ||
10:05 AM – 10:30 AM | Coffee/Tea Break Networking |
Epidemiology – Moderator: Iltefat Hamzavi, MD
Chairpersons: Dr. Dimple Chopra and Dr. Noufal Raboobee
Hours | Abstract # | Topic | Speaker |
---|---|---|---|
10:30 AM – 11:00 AM | Invited Speaker: Burden and Quality of Life in Vitiligo | Khaled Ezzedine, MD, PhD
Click the presenter’s name for additional information. | |
11:00 AM – 11:10 AM | 162 | To What Extent Do Patient Demographics, Clinical Characteristics and Psychological Factors Explain Quality of Life in Vitiligo? | Rachel Carafello, MS |
11:10 AM – 11:20 AM | 196 | Predictive Factors of Thyroid Diseases in Vitiligo in Morocco | Laila Benzekri, MD |
11:20 AM – 11:30 AM | N/A | Update on the Global Vitiligo Atlas | Drs. Ezzedine and Mysrore |
11:30 AM – 11:40 AM | 190 | Resident Memory T Cells in Non-segmental Vitiligo | Rana Hilal, MD |
11:40 AM – 11:50 AM | 178 | New Classification and Treatment Outcome of Hand Vitiligo: A Cluster Analysis of 230 Patients | Hyun Jeong Ju, MD, PhD |
11:50 AM – 12:00 PM | 181 | Role of CXCR3 and Its Primary Ligands in Segmental and Non-segmental Vitiligo Pathogenesis | Vinod Kumar, PhD |
12:00 PM – 12:10 PM | 187 | Segmental Vitiligo Pattern and Cutaneous Arterial Vessel Mapping: An Anatomoclinical and Physiopathological Approach | Yvon Gauthier, MD |
12:10 PM – 12:25 PM | Panel Q&A |
Vitiligo Talks: Understanding the Burden of Disease & Pathophysiology
Pfizer Satellite Program – Lunch and Learn
Hours | Topic | Speaker |
---|---|---|
12:25 PM – 12:40 PM | Attendees grab lunch and return to the ballroom | |
12:40 PM – 12:45 PM | Welcome and Introductions | Iltefat Hamzavi, MD |
12:45 PM – 1:05 PM | Outlining Vitiligo: Overview, Epidemiology & Burden of Disease
Interview and audience Q&A | Iltefat Hamzavi, MD |
1:05 PM – 1:25 PM | Controversies & Challenges in the Pathophysiology of Vitiligo
Interview and audience Q&A | Davinder Parsad, MD, FRCP |
1:25 PM – 1:45 PM | Targeting Innate & Adaptive Immunity as a Therapeutic Approach
Interview and audience Q&A | Samia Esmat, MD |
1:45 PM – 2:10 PM | Remaining Unmet Needs & Future Directions in Vitiligo
Panel discussion and audience Q&A | All |
Medical Treatment – Moderator: Samia Esmat, MD
Chairpersons: Dr. Ahmed Alisa, Dr. S Sacchidanand, and Dr. Yashpal Manchanda
Hours | Abstract # | Topic | Speaker |
---|---|---|---|
2:10 PM – 2:40 PM | Invited Speaker: Update on Jak Inhibitors For Vitiligo | Amit G. Pandya, MD
Click the presenter’s name for additional information. | |
2:40 PM – 2:50 PM | 211 | Combinatorial Therapies With Basic Fibroblast Growth Factor Related Agonist Peptides to Treat Vitiligo | Abburi Ramaiah, PhD |
2:50 PM – 3:00 PM | 193 | Effect of Ruxolitinib Cream on Achievement of VASI50 by Body Region: Week 52 Pooled Analysis of the TRuE-V Phase 3 Studies | Thierry Passeron, MD, PhD |
3:00 PM – 3:10 PM | 142 | Effect of Narrow Band Ultraviolet B on the Tissue Level of Interleukin 15 and Interleukin 15 Receptor Alpha Subunit in Active Non Segmental Vitiligo Cases: An Interventional Cohort Study | Rania Mogawer, MBBch, MSc, MD |
3:10 PM – 3:20 PM | 175 | NB-UVB Phototherapy Response of Different Body Regions in Non-segmental Vitiligo | Vidhya Narayan, MD |
3:20 PM – 3:30 PM | 140 | Azathioprine Monotherapy vs Azathioprine-NB-UVB vs OMP-NB-UVB in Controlling Active Vitiligo, A Randomized, Controlled Study | Marwa Abdallah, MD |
3:30 PM – 3:40 PM | 194 | Complimentary and Alternative Medicine Use in Vitiligo Patients | Marissa Ceresnie, DO |
3:40 PM – 3:50 PM | 176 | Combination of Acitretin and Narrowband UV-B for the Treatment of Vitiligo: A New Treatment Modality With an Impact on Tissue E-cadherin Expression | Samia Esmat, MD |
3:50 PM – 4:20 PM | Invited Speaker: Mimickers of Vitiligo | Trilokraj Tejasvi, MD
Click the presenter’s name for additional information. | |
4:20 PM – 4:35 PM | Panel Q&A | ||
4:35 PM – 5:00 PM | Coffee/Tea Break Networking |
Surgical Management – Moderator: Laila Benzekri, MD
Chairpersons: Dr. T Salim, Dr Fakhriya Khamis Alshibli, and Dr. Sumir Kumar
Hours | Abstract # | Topic | Speaker |
---|---|---|---|
5:00 PM – 5:30 PM | Invited Speaker: Updates on Surgical Management of Vitiligo | Marwa Abdullah, MD
Click the presenter’s name for additional information. | |
5:30 PM – 5:40 PM | 186 | Comparison of Laboratory Indicators and Clinical Efficacy of Non-cultured Epidermal Cell Suspension and Hair Follicle Cell Suspension in Surgical Management of Stable Vitiligo: A Randomized Trial | Somesh Gupta, MD |
5:40 PM – 5:50 PM | 205 | Long-Term Outcomes and Patient Satisfaction With Vitiligo Surgeries | Nikhil Mehta, MD |
5:50 PM – 6:00 PM | 206 | Use of Micro Short Pulse Erbium Yag Laser for Management of Vitiligo and Leukotrekia | Hasan El-Fakahany, MD |
6:00 PM – 6:10 PM | 213 | Motorized 0.5/0.8-Mm Micropunch Grafting to Treat Refractory Vitiligo: A Retrospective Study of 1,066 Cases | Jung Min Bae, MD, PhD |
6:10 PM – 6:20 PM | 197 | Combination of Needling and 308 Excimer Light for Treatment of Vitiligo | Noufal Raboobee, MD |
6:20 PM – 6:30 PM | 141 | Value of Adding Platelet Rich Plasma (PRP) To Non-cultured Epidermal Cell Suspension (NCES) In Surgical Treatment of Stable Resistant Vitiligo: A Self-Controlled Randomized Double-Blinded Study | Rania Mogawer, MBBch, MSc, MD |
6:30 PM – 6:45 PM | Panel Q&A | ||
6:45 PM – 7:00 PM | Wrap up and summary of the day/ Highlights for tomorrow | Dr. Davinder Parsad and Dr. Samia Esmat |
Hours | Topic |
---|---|
7:00 PM – 8:00 PM | Coctail Hour and Networking |
8:00 PM – 9:30 PM | Dinner |